Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002-10-15
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
ABSTRACT
PURPOSE
This trial was prompted by uncertainty about the need for breast irradiation after lumpectomy in node-negative women with invasive breast cancers of
PATIENTS AND METHODS
After lumpectomy, 1,009 women were randomly assigned to TAM (n = 336), XRT and placebo (n = 336), or XRT and TAM (n = 337). Rates of IBTR, distant recurrence, and contralateral breast cancer (CBC) were among the end points for analysis. Cumulative incidence of IBTR and of CBC was computed accounting for competing risks. Results with two-sided P values of.05 or less were statistically significant.
RESULTS
XRT and placebo resulted in a 49% lower hazard rate of IBTR than did TAM alone; XRT and TAM resulted in a 63% lower rate than did XRT and placebo. When compared with TAM alone, XRT plus TAM resulted in an 81% reduction in hazard rate of IBTR. Cumulative incidence of IBTR through 8 years was 16.5% with TAM, 9.3% with XRT and placebo, and 2.8% with XRT and TAM. XRT reduced IBTR below the level achieved with TAM alone, regardless of estrogen receptor (ER) status. Distant treatment failures were infrequent and not significantly different among the groups (P =.28). When TAM-treated women were compared with those who received XRT and placebo, there was a significant reduction in CBC (hazard ratio, 0.45; 95% confidence interval, 0.21 to 0.95; P =.039). Survival in the three groups was 93%, 94%, and 93%, respectively (P =.93).
CONCLUSION
In women with tumors
Related Questions
Would your management change if the patient had extensive DCIS?
New comment by Radiation Oncologist at AdventHealth Orlando (previously Florida Hospital) ( December 15, 2016)
Yikes! That's absolutely not how I intended my response to be interpreted. I certainly agree with you, @Leonard Prosnitz, that using radiation in any disease for the sole bene...
Would multifocality, multicentricity, LVSI, N1mi, etc affect your decision making?
New answer by Radiation Oncologist at Washington University School of Medicine (October 29, 2018)
I wholeheartedly agree with @David E. Wazer and @Leonard Prosnitz. Their answers do take us a few steps away from the original question to the larger issue of what if any...